Details

Published: 05 August 2025

Hits: 1720

A groundbreaking clinical trial published in JAMA Internal Medicine has revealed alarming evidence of CBD liver damage in healthy adults taking doses commonly used by consumers. The US Food and Drug Administration conducted the study, challenging the widespread perception that cannabidiol products are entirely safe and highlighting significant health risks that were previously unrecognised.

CBD Liver Damage Affects 1 in 20 Users in Clinical Trial

The FDA’s randomised double-blind placebo-controlled trial examined 201 healthy participants over 28 days, with 151 receiving CBD at 5mg/kg daily (approximately 400mg for an average adult) and 50 receiving placebo. The results were stark: 8 participants (5.6%) in the CBD group developed liver enzyme elevations greater than three times the normal range, whilst no participants in the placebo group experienced similar effects.

This 5.6% liver toxicity rate from cannabidiol poses a significant health risk, especially since the damage appeared only in laboratory tests while participants felt completely fine. The study’s findings are particularly concerning because they demonstrate liver damage at doses within the range commonly consumed by the general public.

Silent Liver Injury: The Hidden Danger of Cannabidiol Products

Perhaps most troubling is the asymptomatic nature of CBD liver damage observed in the study. Only one participant with elevated enzyme levels experienced symptoms within the four-week window, underscoring that many users may unknowingly experience liver stress without outward signs. This silent progression of liver injury means that consumers using CBD products could be causing significant harm to their bodies without realising it.

The study revealed that seven participants experienced potential drug-induced liver injury, with elevated liver enzymes that can indicate serious cellular damage. Most concerning was that five participants developed liver enzyme levels exceeding five times the normal range, with two reaching levels greater than ten times normal.

Women Face Higher Risk of CBD-Related Liver Toxicity

The research uncovered a particularly alarming pattern regarding cannabidiol liver toxicity and gender. Women appeared to be more vulnerable to liver damage from CBD use, with five of the eight participants experiencing elevated liver enzymes being female. This finding suggests that women may be at disproportionately higher risk when using CBD products.

The study also documented concerning immune system responses alongside liver damage. The majority of participants who experienced the most serious liver problems also developed signs of eosinophilia, an immune condition characterised by excess white blood cells. This dual impact on both liver function and immune response raises serious questions about the broader health implications of CBD consumption.

Consumer CBD Doses Proven Dangerous in Controlled Testing

The FDA study specifically examined doses representative of real-world consumer use, making the findings particularly relevant to current market practices. Daily CBD intake of approximately 400mg, reflecting high consumer use, was associated with liver enzyme elevations in 5.6% of healthy adults. This dose falls well within the range that many consumers report using, with some surveys indicating that 23% of CBD users consume more than 200mg daily.

The CBD liver damage documented in this study occurred despite using pharmaceutical-grade CBD to eliminate contaminants found in unregulated products. This means the liver toxicity observed was directly attributable to CBD itself, not to impurities or adulterants commonly found in over-the-counter products.

Long-Term Implications Remain Unknown

While the study documented liver enzyme elevations returning to normal within one to two weeks after discontinuation, these are the first findings to suggest that even “low-dose CBD,” in the absence of other drugs, may pose a risk to liver health. The implications for long-term users remain unclear, as the study only examined 28 days of use.

The research highlighted several critical knowledge gaps. The study included only healthy participants aged 18-55 without comorbidities or concurrent medications, potentially underestimating risks in the general population. Many CBD users have underlying health conditions, take medications, or belong to age groups not represented in this trial, all factors that could increase susceptibility to cannabidiol liver toxicity.

Regulatory Oversight Urgently Needed

The study’s findings underscore the inadequacy of current regulatory frameworks surrounding CBD products. Such concerns were initially described following an FDA review of clinical trial data on CBD-based prescription drugs for childhood epilepsy, with raised liver enzymes being observed in 14% of participants. Despite these earlier warnings, unregulated CBD products remain widely available to consumers without adequate safety information.

The research suggests that routine monitoring may be necessary for CBD users, particularly those with existing liver conditions or those taking medications metabolised by the liver. Experts suggest incorporating CBD usage into routine medical screening to identify potential liver damage before it becomes clinically apparent.

The Need for Evidence-Based Caution

This FDA study represents the most rigorous examination to date of CBD liver damage at consumer-relevant doses. The findings challenge industry claims about CBD’s safety profile and highlight the urgent need for comprehensive regulatory oversight of cannabidiol products. With millions of consumers regularly using CBD products, even a 5.6% incidence rate of liver injury represents a significant public health concern.

The research demonstrates that CBD is not the benign substance many consumers believe it to be. The combination of silent liver injury, gender-specific vulnerabilities, and immune system effects reveals a complex toxicity profile that demands serious attention from health authorities and consumers alike.

As the popularity of CBD products continues to grow, this study serves as a crucial warning about the potential for serious health consequences from substances marketed as natural wellness products. The evidence clearly indicates that cannabidiol liver toxicity is a real and measurable risk that consumers need to understand before using these products.

(Source: JAMA Network)

Details

Published: 23 July 2025

Hits: 410

The landscape of cannabis and sleep research presents a troubling pattern that has persisted for decades. A regular feature of almost all research reviews, studies and trials on cannabis invariably land with two consistent themes and/or caveats: 1) No conclusive evidence as to the claims, but possible… and 2) More research needed! This pattern is strikingly evident in the current body of literature examining marijuana sleep disorders, where decades of investigation have yielded frustratingly inconclusive results.

Four Decades of Cannabis and Sleep Research

For over 40 years, we have been engaged in researching this now heavily engineered and entirely unnatural plant. Between 1985 and 2025, researchers conducted well over 10,000 reports, studies, and trials examining the benefits and harms of cannabis—at a staggering cost of $4.5 billion USD. Yet despite this massive investment, the outcome has been remarkably limited: only one new FDA-approved medication has emerged in the U.S., while just three other cannabis-based drugs—approved decades ago—remain in use.

Three recent comprehensive reviews paint a concerning picture of cannabis and sleep research. Babson et al. (2017) summarised research up to 2014 and detailed subsequent findings, concluding that “research on cannabis and sleep is in its infancy and has yielded mixed results.” Their review found preliminary suggestions that cannabidiol (CBD) might have therapeutic potential for insomnia, whilst delta-9 tetrahydrocannabinol (THC) may decrease sleep latency but could impair long-term sleep quality.

Limited Evidence for Cannabis and Sleep Benefits

The systematic review by Velzeboer et al. (2022) examined 31 studies specifically focusing on dosing and administration for marijuana sleep disorders. Their findings were hardly encouraging: sleep improvements were observed in only 7 out of 19 randomised studies and 7 out of 12 uncontrolled trials. Whilst subjective improvements in sleep quality were sometimes reported, diagnostic testing revealed no actual improvements in sleep architecture. The researchers concluded that “high-quality evidence to support cannabis use for sleep remains limited.”

Perhaps most tellingly, the qualitative scoping review by Amaral et al. (2023) analysed 40 publications spanning five decades. The results were sobering. While cannabis improved sleep in just 21% of studies, 48% reported worse sleep outcomes. Additionally, 14% showed mixed results, and 17% found no impact at all. Ultimately, the authors concluded with stark honesty: “Our findings summarise the lack of robust evidence to support the use of cannabis for sleep disorders.”

The Heterogeneity Problem in Marijuana Sleep Disorders Studies

The research consistently highlights a fundamental problem: the extreme variability in cannabis products, dosing, administration methods, and outcome measures makes meaningful conclusions nearly impossible. As Velzeboer et al. noted, “Heterogeneity in cannabis types, doses, timing of administration, and sleep outcome measures limit the ability to make specific dosing recommendations.”

This heterogeneity isn’t merely a methodological inconvenience—it reflects the inherent unpredictability of cannabis as a therapeutic agent. Unlike traditional pharmaceuticals with standardised active compounds and predictable pharmacokinetics, cannabis contains hundreds of chemical constituents that vary dramatically between products, batches, and individual responses.

The research reveals a troubling disconnect between subjective reports and objective measurements in cannabis and sleep studies. While many users claimed their sleep had improved, multiple studies found otherwise. Polysomnographic assessments—the gold standard for analysing sleep architecture—consistently showed no actual improvements. This contrast suggests that much of the perceived benefit may stem from a placebo effect, likely amplified by the psychoactive properties of THC, which can induce a subjective sense of relaxation or sedation without producing real improvements in sleep quality.

Public Health Implications and Collateral Harms

The question is: after four decades of researchers relentlessly studying and manipulating this complex plant without producing anything close to “good medicine,” how many more decades and billions of pounds will governments and industries waste on promoting a propagandised plant?

More concerning is the mounting evidence of public health harms already incurred. Studies on cannabis and sleep document adverse events including headaches, sedation, and dizziness occurring more frequently at higher doses. But these pale in comparison to the broader societal costs: billions of pounds lost and lives harmed through road and workplace accidents, mental health deterioration, addiction, and cannabis hyperemesis syndrome manifestations. The social and emotional costs to families and communities from this heavily marketed psychotropic substance continue to accumulate.

The cannabis and sleep research literature exemplifies a broader paradox in cannabis medicine: the more rigorously we study it, the less promising it appears. Early observational studies and anecdotal reports suggested significant benefits, but as researchers improve methodological quality and reduce bias, the positive effects diminish or disappear entirely.

Amaral et al. found that only 25% of the studies they reviewed were randomised controlled trials—the gold standard in medical research. The majority relied on observational data or uncontrolled studies, which are particularly susceptible to bias and confounding variables. This methodological weakness has allowed inflated claims about cannabis efficacy to persist despite lacking solid evidence.

Evidence-Based Medicine vs Marketing Hype

The current state of research should serve as a cautionary tale about the dangers of allowing marketing to precede science. Whilst researchers continue to call for “more research”—a refrain that has echoed for four decades—perhaps it’s time to acknowledge that extensive investigation has already provided an answer: cannabis does not appear to be effective medicine for marijuana sleep disorders.

The three comprehensive reviews examined here, spanning decades of research and thousands of patients, consistently point to the same conclusion: there is insufficient evidence to support cannabis and sleep treatment, and what evidence exists suggests limited efficacy coupled with concerning adverse effects.

Instead of pouring billions into researching a substance that has consistently failed to show clear therapeutic benefits, researchers and funders should focus on developing evidence-based sleep treatments- ones that work reliably, have predictable effects, and avoid the significant risks linked to regular cannabis use.

The Reality After Four Decades of Investment

After 40 years and $4.5 billion in research investment, the literature tells a clear story: cannabis is not a reliable treatment for sleep—and it may never be. Yet despite this, calls for “more research” persist. Increasingly, these appeals seem less rooted in scientific rigour and more like an attempt to move the goalposts, avoiding the uncomfortable truth about a substance that continues to be heavily promoted despite weak evidence.

The real challenge for public health officials, clinicians, and policymakers is not the need for more research, but whether they’re ready to prioritise evidence-based medicine over marketing hype—and to honestly weigh the full financial and human costs of promoting cannabis as medicine when the science doesn’t support it.

As Amaral and colleagues concluded, cannabis for sleep disorders is “not ready for prime time.” Given four decades of research reaching the same conclusion, perhaps it’s time to accept that it never will be.

(Source: WRD News)

Details

Published: 23 July 2025

Hits: 589

The convergence of early initiation, increasing product potency, and widespread availability has reshaped the contemporary cannabis landscape, heightening concerns about its impact on adolescent mental health. Translational research combining longitudinal human neuroimaging and animal models provides compelling evidence that cannabis use—particularly with high-tetrahydrocannabinol (THC) products and frequent use—can disrupt adolescent brain development and behavior. This vulnerability is especially relevant to trajectories leading to psychosis, schizophrenia, and cannabis use disorder, while also elevating risks for anxiety and depression. Although not all adolescents who use cannabis will experience adverse outcomes, a susceptible subset may face lasting consequences. These risks underscore the urgent need for targeted public education and innovative clinical research to mitigate cannabis-associated harms. Encouragingly, emerging neurobiological findings suggest that not all cannabis-induced brain changes persist into adulthood. Epigenetic mechanisms implicated in the long-term effects of THC exposure further indicate that some neural and behavioral alterations may be reversible. Given the high plasticity of the adolescent brain, this evidence points to a critical window for prevention and early intervention strategies capable of altering the course of cannabis-related psychopathology and supporting more resilient developmental outcomes. (Source:Publication: American Journal of Psychiatry Volume 182, Number 7; https://doi.org/10.1176/appi.ajp.20250444)

Also see 

• Teen Cannabis Use and Psychosis Risk is now 11 Fold
• Pot-related psychosis linked to early ‘dangerous’ use
• Cannabis and Young Minds: Mental Health Risks and Prevention

Details

Published: 23 July 2025

Hits: 376

How regulatory capture, commercial greed, and political cowardice created a cannabis prescription mill masquerading as healthcare

Australia’s medicinal cannabis system stands as a damning indictment of what happens when politics trumps science, profit overrides patient safety, and regulatory agencies abandon their fundamental duty to protect public health. What began in 2016 as a compassionate response to desperate families seeking treatment for children with intractable epilepsy has devolved into what critics accurately describe as a “commercial monster” – a barely regulated cannabis prescription mill where doctors write cannabis scripts every four minutes and patients receive industrial-strength THC products after cursory phone consultations.

The statistics alone reveal a system utterly divorced from medical oversight. In 2024, the Therapeutic Goods Administration (TGA) authorised at least 979,000 prescription applications for medicinal cannabis through its “specialised access” pathways – mechanisms originally designed for occasional, case-by-case use of unapproved drugs that have now become mainstream distribution channels for cannabis products.

The Regulatory Door Left Wide Open: The TGA’s fundamental failure lies in creating loopholes that allow “unapproved medicines” to bypass the rigorous safety, quality, and efficacy testing required of legitimate pharmaceuticals. By establishing Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways that circumvent normal drug approval processes, the TGA essentially abdicated its primary responsibility to protect public health.

Most medicinal cannabis products available in Australia – save for two with TGA approval – lack the evidence demonstrating safety, quality, and efficacy required of registered pharmaceuticals. These products rely on what regulators euphemistically call “compassion” and “exceptionality” – code words for abandoning scientific standards in favour of political expediency.

The TGA openly admits that “unapproved therapeutic goods accessed through these pathways have not been evaluated by the TGA for safety, quality and efficacy.” Yet regulators continue to permit the prescription of these untested substances to vulnerable patients, including those with serious mental health conditions. This represents a two-tiered medical system where cannabis receives special treatment unavailable to any other therapeutic substance.

The Prescription Mill Reality: The transformation of medical practitioners into what one doctor described as “glorified cannabis dealers” represents a fundamental corruption of the medical profession. Eight practitioners issued more than 10,000 medicinal cannabis prescriptions in just six months, whilst one appeared to have issued over 17,000 scripts in the same period. These numbers make adequate patient care mathematically impossible.

A single pharmacist dispensed nearly one million cannabis products annually – that’s 2,600 products every single day for an entire year without respite. These statistics don’t reflect a carefully managed medical programme; they reveal a cannabis prescription mill operating under the thin veneer of healthcare legitimacy.

Dr Claire Noonan’s experience exposes the insidious pressure applied to healthcare providers: “There was a bit of pressure to be, perhaps more of a dealer… it’s more being used for my signature on a script.” When doctors earn money based on the number of prescriptions they write, when companies pressure practitioners to override their clinical judgment, and when nurses without medical training conduct “consultations,” the system ceases to be medicine and becomes a sophisticated drug distribution network.

Evidence Deficit: The TGA’s Own Damning Admissions: Despite over 11,420 studies on cannabis THC alone costing $4.877 billion, the evidence remains woefully inadequate. The TGA’s own clinical guidance, last comprehensively updated in 2017, starkly acknowledges the paucity of solid evidence supporting medicinal cannabis use across most conditions.

For chronic pain – the most common reason medicinal cannabis is prescribed in Australia – the evidence quality ranges from “low to moderate” to “very low.” The TGA guidance explicitly states there is “insufficient information to make a conclusion about cannabinoids for the treatment of pain associated with arthritis and fibromyalgia,” yet these are amongst the most common prescribing indications.

In multiple sclerosis, five of ten studies showed some benefit, but the other five were “inconclusive or did not show that treatment with cannabinoids had any positive effect.” For palliative care, the guidance is damning: “there is little evidence of any benefit to advanced cancer patients with chronic pain” and “no evidence that medicinal cannabis has any anti-cancer activity in human studies.”

Most tellingly, the guidance emphasises that “there is no information available on the most effective or safe dose for various conditions and symptoms.” This fundamental knowledge gap hasn’t prevented the mass prescribing of products containing up to 34% THC – concentrations the guidance would classify as dangerous for most patients.

Dosing in the Dark: The Knowledge Vacuum: Perhaps the most damning indictment of the current system lies in the TGA’s own admission: “There is no information available on the most effective or safe dose for various conditions and symptoms.” This fundamental knowledge gap renders the entire prescribing enterprise experimental at best, dangerous at worst.

The clinical guidance emphasises that “starting doses should be low and increased over time until patients respond positively or the negative effects outweigh the perceived benefits.” It specifically warns that “low start doses are particularly important for people with memory and thinking difficulties, liver and kidney disease, and weakness and wasting of the body due to severe chronic illness. Low start doses are also important for young people and the elderly.”

Yet the reality described by patients and practitioners reveals a system doing precisely the opposite. Doctors routinely prescribe high-strength products after brief consultations, often disregarding the “start low, go slow” principle, which is the only safe approach given our limited knowledge.

The guidance explicitly acknowledges that “most of the studies reported in the medical literature have either used purified pharmaceutical substances or smoked cannabis” rather than the “whole plant products that are currently available.” This means practitioners are essentially prescribing products that haven’t been studied, at doses that haven’t been established, for conditions where efficacy hasn’t been proven.

The Side Effects Catalogue: Known Dangers, Ignored Warnings: The TGA guidance provides an extensive catalogue of known side effects that reads like a litany of reasons for caution. For CBD and THC products combined, documented side effects include “fatigue and sedation, vertigo, nausea and vomiting, fever, decreased or increased appetite, dry mouth, and diarrhoea.”

For THC-containing products specifically, the warnings are more severe: “convulsions, feeling high or feeling dissatisfied, depression, confusion, hallucinations, paranoid delusions, psychosis, and cognitive distortion.” The guidance notes that “in general, the side effects of CBD-rich products are less than those for high-THC products, but because the required doses for CBD can be quite high in conditions such as paediatric epilepsies, a proportion of patients encounter side-effects with these CBD doses.”

These aren’t theoretical concerns. The guidance emphasises that “patients with neurological conditions may be more likely to experience negative effects from medicinal cannabis” and that there is “very limited evidence to show how medicinal cannabis reacts with other approved medications.”

The TGA guidance specifically warns that THC products can cause convulsions, feeling high or dissatisfied, depression, confusion, hallucinations, paranoid delusions, psychosis, and cognitive distortion. It explicitly states that doctors should not prescribe medicinal cannabis to people with an active or previous psychotic disorder or an active mood or anxiety disorder yet these are precisely the conditions for which they now routinely prescribe it.

The Mental Health Catastrophe: Perhaps most damning is the mounting evidence of mental health catastrophes directly linked to these prescribing practices—outcomes that experts could have easily predicted based on the TGA’s own safety warnings. The clinical guidance explicitly states that medicinal cannabis is “not appropriate for people with an active or previous psychotic or active mood or anxiety disorder,” yet doctors now routinely prescribe it for exactly these conditions.

Patients like Rohan Dawson, who received 27% THC cannabis that left him feeling “on Pluto” and significantly worsened his anxiety, represent predictable outcomes when profit trumps patient safety and clinical guidance is ignored. Recent reports document significant increases in hospitalisations due to psychosis amongst patients prescribed medicinal cannabis. Some patients with pre-existing mental health conditions experience severe relapses, with documented cases of patients developing psychosis requiring hospitalisation and tragically, at least one suicide following medicinal cannabis prescription.

The irony is palpable: the TGA guidance acknowledges there are “currently no studies that compare medicinal cannabis products to the most effective and commonly used medications for MS pain and spasticity” and that “current studies show no evidence that medicinal cannabis can improve overall quality of life or physical functioning.” Yet practitioners continue prescribing high-THC products for conditions where safer, proven alternatives exist.

Professor Ian McGregor’s warnings about high-THC products prove prophetic: “Higher-THC products appear to be more linked to mental health adverse outcomes, precipitation of severe anxiety and paranoia in vulnerable individuals, perhaps schizophrenia and manic attacks.”

Driving Under the Influence: A Public Safety Crisis: The TGA guidance contains a stark warning that has been systematically ignored: “Patients should not drive or operate machinery while being treated with medicinal cannabis.” It specifically notes that “measurable concentrations of THC can be detected in urine many days after the last dose” and that “it may take up to five days for 80 to 90 per cent of the dose to be excreted.”

With nearly one million prescriptions authorised in 2024 alone, Australia now has hundreds of thousands of people potentially driving whilst impaired by prescribed THC products. The guidance explicitly states that “drug-driving is a criminal offence” and advises patients to “discuss the implications for safe and legal driving with their doctor.” Yet there’s no evidence this crucial safety counselling is occurring in the high-volume telehealth consultations that dominate the industry.

Marketing Manipulation and Commercial Exploitation: Despite the evidence deficit and clear safety warnings, aggressive marketing campaigns would make pharmaceutical executives blush. Research examining 54 private medicinal cannabis clinic websites found widespread examples of aggressive and misleading marketing, including unsubstantiated health claims, self-assessment tools that “coach” patients on which conditions might warrant prescriptions, and promises of same-day delivery with no GP referrals required.

Companies run over 170 active advertisements monthly across Facebook, Instagram, and Threads, targeting young people as young as 18 with cryptic messaging such as “we can’t shout about it, but our patients are smiling” paired with wellness-themed imagery. One advertisement promises “real doctors, real care” and “fast approvals & express delivery” with consultations at just $19.

The Subscription Model of Dependency: Most sinister is the industry’s adoption of subscription models that ensure patients continue receiving cannabis products regardless of their medical needs or outcomes. Patients like Rohan Dawson, who discontinued treatment due to adverse effects, continued to receive automatic shipments and bills: “Despite never having another appointment, he continued to be billed under a subscription model and more cannabis arrived at his door.”

This isn’t healthcare – it’s a drug dealing operation with automatic billing. When prescription cannabis achieves “cost parity with illicit products,” and when practitioners boast about convenience rather than efficacy, the medical pretence becomes impossible to maintain.

The Research That Never Happened: The TGA guidance concludes with a stark admission that there is “a significant need for larger, high-quality studies to better explore the potential benefits, limitations and safety issues associated with medicinal cannabis treatment across a range of health conditions and symptoms.” The guidance acknowledges the need for research to:

• Increase the amount and quality of evidence to either support or contradict the use of medicinal cannabis
• Give a more detailed understanding of the most effective cannabis products, doses and administration methods
• Compare medicinal cannabis with standard first line medication options
• Build a strong knowledge base on how medicinal cannabis interacts with other drug treatments

This research agenda, outlined in 2017, remains largely unfulfilled seven years later. Instead of conducting the necessary studies to establish safety and efficacy, the system has allowed mass prescribing to proceed based on commercial pressure rather than clinical evidence.

Australia has essentially conducted an uncontrolled population-level experiment with nearly one million cannabis prescriptions, whilst simultaneously failing to collect the data necessary to determine whether the experiment is succeeding or causing harm.

Regulatory Capture and Political Cowardice: The current crisis stems from what the Dalgarno Institute correctly identifies as the “vote for medicine” protocol – a deliberate strategy to bypass rigorous clinical trials and scientific evidence in favour of emotional manipulation and political pressure. The Victorian Law Reform Commission’s 2014 consultation exemplified manufactured consent, drawing from merely 99 submissions and poorly attended public hearings dominated by cannabis advocates.

The Australian Health Practitioner Regulation Agency’s (Ahpra) recent announcement of a “crackdown” on unsafe prescribing represents too little, too late. By merely repeating existing rules rather than tightening them, Ahpra has missed a crucial opportunity to safeguard patients’ health.

International Warnings Ignored: Australia’s headlong rush into medicinal cannabis occurred despite mounting international evidence of problems. North American reports of rising cannabis-related disorders amongst older adults, increasing emergency department visits, and growing recognition of cannabis use disorder should have provided cautionary lessons. Instead, Australian policymakers chose to ignore these warnings in favour of industry lobbying and political expediency.

The parallels with the opioid crisis are unmistakable: aggressive marketing of high-potency products, regulatory capture, medical professionals pressured to prescribe against their better judgement, and systematic downplaying of addiction risks.

A System Beyond Salvation: Australia’s medicinal cannabis industry represents one of the most egregious failures of medical regulation in the nation’s history. The evidence was always there. The warnings were clear. The outcomes were inevitable. What’s inexcusable is that it was allowed to happen anyway.

The current system fails on every metric that matters: patient outcomes, medical ethics, regulatory oversight, and public health protection. Until Australia acknowledges that its medicinal cannabis programme has become a cannabis prescription mill masquerading as healthcare, more patients will suffer the predictable consequences of prioritising politics over patient safety.

The transformation from compassionate access programme to commercial monster didn’t happen by accident. It resulted from deliberate policy choices that favoured industry profits over patient welfare, political expedience over scientific rigour, and regulatory capture over public health protection.

The only question remaining is how many more casualties this system will claim before sanity prevails. The cannabis industry’s corruption of Australian healthcare represents not just a policy failure, but a moral catastrophe that demands immediate and comprehensive reform. Anything less condemns more vulnerable patients to become casualties of a system that has forgotten its fundamental duty: first, do no harm. (Source:WRD News)